Organization
Takarazuka City Hospital
3 abstracts
Abstract
Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).Org: Kobe Minimally Invasive Cancer Center, Hakodate Goryoukaku Hospital, Fujita Health University Hospital, Onomichi General Hospital, Takarazuka City Hospital,
Abstract
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).Org: Kobe Minimally Invasive Cancer Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan, Takarazuka City Hospital, Hyogo Medical University, Kurashiki Central Hospital, Kurashiki, Japan,
Abstract
ASSOCIATION BETWEEN DISEASE ACTIVITY AND CHANGES IN FIBROSIS-4 INDEX LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH METHOTREXATE FOR A SHORT PERIODOrg: Hyogo Medical University, Division of Allergology and Rheumatology, Department of Internal medicine №1, Nishinomiya, Japan, Takarazuka City Hospital,